Prospective intervention study of novel SGLT-2 inhibitor ipragliflozin in patients with type 2 diabetes

Trial Profile

Prospective intervention study of novel SGLT-2 inhibitor ipragliflozin in patients with type 2 diabetes

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 May 2016

At a glance

  • Drugs Ipragliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Apr 2016 Status changed from recruiting to active, no longer recruiting.
    • 25 Aug 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan
    • 12 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top